Triptorelin
An FDA-approved GnRH agonist used for prostate cancer, endometriosis, central precocious puberty, and discussed in the peptide community for post-cycle hormonal resets.
What is Triptorelin?
Triptorelin is a synthetic decapeptide GnRH superagonist (pGlu-His-Trp-Ser-Tyr-D-Trp-Leu-Arg-Pro-Gly-NH2) that is 13- to 21-fold more potent than native GnRH. A D-tryptophan substitution at position 6 confers enhanced receptor affinity and resistance to enzymatic degradation. Like other GnRH agonists, continuous administration causes an initial gonadotropin flare followed by profound pituitary desensitization, leading to medical castration levels of sex hormones. Triptorelin was first FDA-approved in 2000 (Trelstar) for advanced prostate cancer, and in 2017 (Triptodur) for central precocious puberty. It is also widely used internationally for endometriosis and as part of IVF protocols.
Why People Talk About It
Advanced prostate cancer treatment (androgen deprivation therapy)
StrongCentral precocious puberty management
StrongEndometriosis symptom relief and post-surgical recurrence prevention
StrongIVF protocols (pituitary suppression for controlled ovarian stimulation)
StrongPost-cycle therapy (single-dose hormonal reset after anabolic steroid use)
LimitedHow It Works
Triptorelin mimics the brain's natural GnRH hormone but is far more potent and long-lasting. When given continuously (via depot injection), it overwhelms the pituitary's GnRH receptors, causing them to shut down. This stops LH and FSH production, which in turn halts testosterone and estrogen production — effectively a reversible chemical castration useful for hormone-sensitive cancers and conditions.
Common Questions
Safety Information
Common Side Effects
Cautions
- • Initial testosterone flare can worsen prostate cancer symptoms — anti-androgen cover often needed
- • Long-term use causes bone mineral density loss
- • Increased cardiovascular risk (heart attack, stroke), especially with existing heart disease
- • Metabolic changes including increased risk of diabetes and hyperlipidemia
- • Not for use in pregnancy — can cause fetal harm
- • Overdose in PCT context (>100mcg) risks prolonged castration-level suppression
What We Don't Know
Well-characterized safety profile with over 25 years of clinical use across multiple indications. Long-term cardiovascular and metabolic effects are actively monitored. The off-label single-dose PCT use has no formal safety data.
Published Research
16 studiesTreatment of aggressive prostate cancer with triptorelin in real life in France: the TALISMAN study
Short-term Androgen Deprivation Therapy and High-dose Radiotherapy in Intermediate- and High-risk Localized Prostate Cancer: Results from the GETUG 14 Randomized Phase 3 Trial
PRIORITI: Phase 4 study of triptorelin or active surveillance in high-risk prostate cancer
Triptorelin therapy for lower urinary tract symptoms (LUTS) in prostate cancer patients: A systematic meta-analysis
The use of post-cycle therapy is associated with reduced withdrawal symptoms from anabolic-androgenic steroid use: a survey of 470 men
Efficacy and Safety of Triptorelin 3-Month Formulation in Chinese Children with Central Precocious Puberty: A Phase 3, Open-Label, Single-Arm Study
Adverse cardiovascular effect following gonadotropin-releasing hormone antagonist versus GnRH agonist for prostate cancer treatment: A systematic review and meta-analysis
Assessment of Two Formulations of Triptorelin in Chinese Patients with Endometriosis: A Phase 3, Randomized Controlled Trial
Gonadotropin-releasing hormone agonists in prostate cancer: A comparative review of efficacy and safety
Decreased testosterone recovery after androgen deprivation therapy for prostate cancer
Are all gonadotrophin-releasing hormone agonists equivalent for the treatment of prostate cancer? A systematic review
Luteinizing Hormone-Releasing Hormone Agonists are Superior to Subcapsular Orchiectomy in Lowering Testosterone Levels of Men with Prostate Cancer: Results from a Randomized Clinical Trial
An Update on Triptorelin: Current Thinking on Androgen Deprivation Therapy for Prostate Cancer
Triptorelin for the treatment of endometriosis
A randomized study comparing triptorelin or expectant management following conservative laparoscopic surgery for symptomatic stage III-IV endometriosis
Comparison of leuprolide acetate and triptorelin in assisted reproductive technology cycles: a prospective, randomized study
Related Peptides
Leuprolide
StrongAn FDA-approved GnRH agonist used for prostate cancer, endometriosis, and precocious puberty through hormonal suppression.
Gonadorelin
StrongSynthetic gonadotropin-releasing hormone used diagnostically and therapeutically for reproductive hormone assessment and fertility.
Kisspeptin
ModerateA naturally occurring neuropeptide that plays a central role in reproductive hormone regulation and fertility.
Quick Facts
- Class
- GnRH Agonist
- Evidence
- Strong
- Safety
- Well-Studied
- Updated
- Apr 2026
- Citations
- 16PubMed
Also known as
Tags
Related Goals
Evidence Score
Clinical Trials
View Clinical TrialsLinks to ClinicalTrials.gov for reference. Listing does not imply endorsement.